Q-omics provides the consensus-scored PCDHB19P profile across patient tissues and cancer cell-line models. PCDHB19P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PCDHB19P is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PCDHB19P RNA expression shows 17,022 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where PCDHB19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB19P survival associations across molecular data types. PCDHB19P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB19P RNA expression–survival associations across cancer types. High PCDHB19P expression shows favorable associations in HNSC, UCS, SKCM, THYM, READ and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PCDHB19P RNA expression.
This table summarizes PCDHB19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHB19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB19P shows lower tumor expression in THCA, UCEC and BRCA and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher PCDHB19P RNA expression in tumor versus normal tissue (log2 FC = +0.213, t-test p < 0.001).
This table shows molecular features associated with PCDHB19P in patient tissues and cancer cell lines. In patient samples, PCDHB19P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
